Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Hospitalized Patients With and Without Hemodialysis Have Markedly Different Vancomycin Pharmacokinetics: A Population Pharmacokinetic Model-Based Analysis.

Goti V, Chaturvedula A, Fossler MJ, Mok S, Jacob JT.

Ther Drug Monit. 2018 Apr;40(2):212-221. doi: 10.1097/FTD.0000000000000490.

PMID:
29470227
2.

Initial dosage regimens of vancomycin for Chinese adult patients based on population pharmacokinetic analysis.

Deng C, Liu T, Zhou T, Lu H, Cheng D, Zhong X, Lu W.

Int J Clin Pharmacol Ther. 2013 May;51(5):407-15. doi: 10.5414/CP201842.

PMID:
23458230
3.

Investigation of the age dependency of vancomycin clearance by population pharmacokinetic modeling.

Usman M, Fobker M, Hempel G.

Int J Clin Pharmacol Ther. 2018 Feb;56(2):56-63. doi: 10.5414/CP203033.

PMID:
29319495
4.

Urea kinetics and dialysis treatment time predict vancomycin elimination during high-flux hemodialysis.

Schaedeli F, Uehlinger DE.

Clin Pharmacol Ther. 1998 Jan;63(1):26-38.

PMID:
9465839
5.

Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation.

Revilla N, Martín-Suárez A, Pérez MP, González FM, Fernández de Gatta Mdel M.

Br J Clin Pharmacol. 2010 Aug;70(2):201-12. doi: 10.1111/j.1365-2125.2010.03679.x.

6.

Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.

Narwal R, Roskos LK, Robbie GJ.

Clin Pharmacokinet. 2013 Nov;52(11):1017-27. doi: 10.1007/s40262-013-0085-2.

7.

Initial vancomycin dosing protocol to achieve therapeutic serum concentrations in patients undergoing hemodialysis.

Zelenitsky SA, Ariano RE, McCrae ML, Vercaigne LM.

Clin Infect Dis. 2012 Aug;55(4):527-33. doi: 10.1093/cid/cis458. Epub 2012 May 9.

PMID:
22573855
8.

Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease.

Zhao W, Zhang D, Fakhoury M, Fahd M, Duquesne F, Storme T, Baruchel A, Jacqz-Aigrain E.

Antimicrob Agents Chemother. 2014 Jun;58(6):3191-9. doi: 10.1128/AAC.02564-13. Epub 2014 Mar 24.

9.

Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants.

Chen Y, Wu D, Dong M, Zhu Y, Lu J, Li X, Chen C, Li Z.

Eur J Clin Pharmacol. 2018 Jul;74(7):921-930. doi: 10.1007/s00228-018-2454-0. Epub 2018 Mar 30.

PMID:
29602981
10.

Population pharmacokinetic parameters of vancomycin in critically ill patients.

Llopis-Salvia P, Jiménez-Torres NV.

J Clin Pharm Ther. 2006 Oct;31(5):447-54.

PMID:
16958822
11.

Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance.

Anderson BJ, Allegaert K, Van den Anker JN, Cossey V, Holford NH.

Br J Clin Pharmacol. 2007 Jan;63(1):75-84. Epub 2006 Jul 21.

12.

Pharmacokinetics of vancomycin and dosing recommendations for trauma patients.

Medellín-Garibay SE, Ortiz-Martín B, Rueda-Naharro A, García B, Romano-Moreno S, Barcia E.

J Antimicrob Chemother. 2016 Feb;71(2):471-9. doi: 10.1093/jac/dkv372. Epub 2015 Nov 14.

PMID:
26568565
13.

Population pharmacokinetics of vancomycin in neonates.

Seay RE, Brundage RC, Jensen PD, Schilling CG, Edgren BE.

Clin Pharmacol Ther. 1994 Aug;56(2):169-75. Erratum in: Clin Pharmacol Ther 1995 Aug;58(2):142.

PMID:
8062493
14.

Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy.

Economou CJP, Kielstein JT, Czock D, Xie J, Field J, Richards B, Tallott M, Visser A, Koenig C, Hafer C, Schmidt JJ, Lipman J, Roberts JA.

Int J Antimicrob Agents. 2018 Aug;52(2):151-157. doi: 10.1016/j.ijantimicag.2018.03.001. Epub 2018 Mar 9.

PMID:
29526606
15.

Optimised dosing of vancomycin in critically ill Indigenous Australian patients with severe sepsis.

Tsai D, Stewart PC, Hewagama S, Krishnaswamy S, Wallis SC, Lipman J, Roberts JA.

Anaesth Intensive Care. 2018 Jul;46(4):374-380.

PMID:
29966110
16.

Population pharmacokinetics and dose simulation of vancomycin in critically ill patients during high-volume haemofiltration.

Escobar L, Andresen M, Downey P, Gai MN, Regueira T, Bórquez T, Lipman J, Roberts JA.

Int J Antimicrob Agents. 2014 Aug;44(2):163-7. doi: 10.1016/j.ijantimicag.2014.03.009. Epub 2014 Apr 28.

PMID:
24837847
17.

Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination.

Lo YL, van Hasselt JG, Heng SC, Lim CT, Lee TC, Charles BG.

Antimicrob Agents Chemother. 2010 Jun;54(6):2626-32. doi: 10.1128/AAC.01370-09. Epub 2010 Apr 12.

18.

Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations.

Mehrotra N, Tang L, Phelps SJ, Meibohm B.

Pharmacotherapy. 2012 May;32(5):408-19. doi: 10.1002/j.1875-9114.2012.01029.x. Epub 2012 Apr 9.

PMID:
22488303
19.

Assessment of Appropriateness of an Initial Dosing Regimen of Vancomycin and Development of a New Dosing Nomogram.

Yoon S, Park KR, Lee S, Song SH, Park WB, Jang IJ, Yu KS.

Basic Clin Pharmacol Toxicol. 2018 Feb;122(2):233-238. doi: 10.1111/bcpt.12873. Epub 2017 Sep 6.

PMID:
28834212
20.

Using clinical data to determine vancomycin dosing parameters.

Birt JK, Chandler MH.

Ther Drug Monit. 1990 Mar;12(2):206-9.

PMID:
2315979

Supplemental Content

Support Center